The estimated Net Worth of Phyllis R Yale is at least $3.4 Million dollars as of 12 May 2023. Ms. Yale owns over 7,165 units of DaVita Inc stock worth over $3,122,147 and over the last 8 years she sold DVA stock worth over $0. In addition, she makes $280,265 as Independent Director at DaVita Inc.
Phyllis has made over 2 trades of the DaVita Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she exercised 7,165 units of DVA stock worth $474,968 on 12 May 2023.
The largest trade she's ever made was exercising 11,757 units of DaVita Inc stock on 22 June 2021 worth over $834,159. On average, Phyllis trades about 274 units every 10 days since 2016. As of 12 May 2023 she still owns at least 20,275 units of DaVita Inc stock.
You can see the complete history of Ms. Yale stock trades at the bottom of the page.
Phyllis R. Yale serves as Independent Director of the Company. She has been an Advisory Partner with Bain & Company, Inc. (“Bain”), a global management consulting firm, since July 2010. Ms. Yale was a Partner with Bain from 1987 to July 2010, and was a leader in building Bain’s healthcare practice. In her role at Bain, Ms. Yale works with healthcare payors, providers, and medical device companies, and frequently advises the world’s leading private equity firms on their investments in the healthcare sector. She has served as a member of the Board of Directors of several public and private companies in the healthcare sector, and currently serves as a member of the Board of Directors of Blue Cross Blue Shield of Massachusetts, a not-for-profit health plan headquartered in Boston and serves on the Board of Directors of Bristol-Myers Squibb Company, a global biopharmaceutical company headquartered in New York City. Ms. Yale previously served as Chair of the Board of Directors of Kindred Healthcare, Inc., a provider of long-term healthcare services in the United States, from January 2010 until July 2018; a Director of National Surgical Hospitals, a privately held specialty hospital operator, which was acquired by Surgery Partners in 2017; and a Director of ValueOptions, Inc., a behavioral health improvement management company specializing in mental and emotional wellbeing and recovery, which merged with Beacon Health Strategies in 2014. Ms. Yale has a deep knowledge base and experience in several segments of the healthcare industry including corporate strategies, marketing and cost and quality management, as well as mergers and acquisitions.
As the Independent Director of DaVita Inc, the total compensation of Phyllis Yale at DaVita Inc is $280,265. There are 15 executives at DaVita Inc getting paid more, with Javier Rodriguez having the highest compensation of $16,853,500.
Phyllis's mailing address filed with the SEC is C/O DAVITA INC, 2000 16TH STREET, DENVER, CO, 80202.
Over the last 22 years, insiders at DaVita Inc have traded over $539,813,199 worth of DaVita Inc stock and bought 20,841,023 units worth $1,590,012,094 . The most active insiders traders include Hathaway Incbuffett Warren ..., R. Ted Weschler,, and Kent J Thiry. On average, DaVita Inc executives and independent directors trade stock every 12 days with the average trade being worth of $12,626,872. The most recent stock trade was executed by Kathleen Alyce Waters on 28 August 2024, trading 26,333 units of DVA stock currently worth $1,999,991.
about davita kidney care davita kidney care is a division of davita healthcare partners inc., a fortune 500® company that, through its operating divisions, provides a variety of health care services to patient populations throughout the united states and abroad. a leading provider of dialysis services in the united states, davita kidney care treats patients with chronic kidney failure and end stage renal disease. davita kidney care strives to improve patients' quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. as of march 31, 2015, davita kidney care operated or provided administrative services at 2,197 outpatient dialysis centers located in the united states serving approximately 174,000 patients. the company also operated 93 outpatient dialysis centers located in 10 countries outside the united states. davita kidney care supports numerous programs dedicated to creating positive,
DaVita Inc executives and other stock owners filed with the SEC include: